Substantial progress has been made in the development of disease modifying therapeutics for Multiple Sclerosis (MS) in recent years. The array of next-generation compounds for this complicated disease have made great strides in increasing the time between relapse and delaying disease progression.
High-quality data are critical when seeking to measure treatment outcomes, but this is especially challenging in rare disease trials where the stakes are high with complex assessments and a limited number of eligible participants. In this webinar, Dr. Pam Ventola will describe customized rater training approaches that meet sponsors’ needs but also are flexible and efficient so to be feasible for sites.
Learn how to leverage integrated digital cognitive assessments and patient reports for advanced insights, streamlined delivery and lower burden. Watch the webinar from ERT and Cogstate to learn the value of assessing cognitive safety and tolerability throughout the drug development process, key considerations for selecting and optimizing computerized cognitive assessments, and more.
As the COVID-19 pandemic spread, research teams worldwide quickly adapted study plans to safely continue research whenever possible. While some observational studies were put on hold entirely, other therapeutic trials were continued with many or all study activities occurring remotely.
Clinical Outcome Assessments in Preclinical Alzheimer’s Disease: Considerations for Global Clinical Trials
Clinical trials designed to study interventions at the preclinical AD stage are using fit-for-purpose clinical outcome assessments that have high validity and reliability for the detection of cognitive change at this early stage of the illness. This webinar outlines the application of several preclinical stage instruments for use in industry clinical trials.
Clinical trials in patients with rare disease present considerable challenges, as patients with these conditions are typically heterogeneous and many are quite impaired. In this webinar, Dr. Pamela Ventola describes important factors to consider when selecting cognitive and behavioral endpoints for these trials and shares strengths and application considerations for several key scales.
In clinical trials, changes in performance on cognitive tests can provide a sensitive index of the impact of a drug on the central nervous system. This webinar details how the detection of decline in specific aspects of cognition, or in cognition in general, is important for making decisions about target engagement, maximum tolerated dose and pharmacodynamic profile.
In recent years the neurocognitive effects of treatments for pediatric cancers have been acknowledged in the scientific literature. However, in many cases the magnitude of these deficits and the long-term impact on cognitive maturation remain unclear. In this webinar Dr. Adrian Schembri and Dr. Kristina Hardy share their collective experience on the application of computerized cognitive assessments in pediatric oncology.
The past two decades have seen multiple industry trials explore the impact of drug treatments on cognition in Parkinson’s disease and PD dementia. In this webinar, our speakers address important trends in the identification of patient populations suitable for trials of cognition-enhancing or disease-modifying therapies.
High-quality data are critical when seeking to measure treatment outcomes, but this is especially true and challenging in rare disease trials. This webinar outlines how clinical trial sponsors are incorporating leading-edge data capture and monitoring strategies to optimize clinical outcome assessments.
Selecting CNS Endpoint Measures in Pediatric and Rare Disease Clinical Trials: Key Considerations for Cognitive and Behavioral Assessments
Testing new medicines in children and patients with rare diseases presents considerable challenges, not the least of which is proper endpoint selection and measurement. This webinar discusses critical considerations when selecting developmental and computerized assessments for children.
The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations
Nearly all patients with central nervous system cancers experience cognitive problems during the course of their disease and treatment that can result in diminished quality of life and functional independence. This webinar discusses the role and relevance of cognitive endpoints in clinical trials to accelerate understanding of cognitive dysfunction related to cancer and cancer treatments.